Patents by Inventor Matthew Boxer

Matthew Boxer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES
    Publication number: 20250066345
    Abstract: The present disclosure provides compounds, compositions comprising them, and pharmaceutical uses thereof, for example, compositions suitable for the treatment of 12 lipoxygenase (12-LOX) mediated diseases.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 27, 2025
    Inventors: David MALONEY, Matthew BOXER
  • AQUEOUS PARENTERAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES
    Publication number: 20250057857
    Abstract: Provided are aqueous pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility. Also provides are aqueous parenteral pharmaceutical formulations comprising selective 12-LOX inhibitors with 2-hydroxyalkyl-?-cyclodextrins.
    Type: Application
    Filed: December 15, 2022
    Publication date: February 20, 2025
    Inventors: David MALONEY, Matthew BOXER, Richard WINNIKE
  • INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
    Publication number: 20240174684
    Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 30, 2024
    Inventors: Robert G. Lowery, Meera Kumar, Matthew Boxer, David Maloney
  • INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS
    Publication number: 20220073470
    Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof.
    Type: Application
    Filed: January 3, 2020
    Publication date: March 10, 2022
    Inventors: Robert G. Lowery, Meera Kumar, Matthew Boxer, David Maloney, Susan Boyd
  • INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS
    Publication number: 20220073532
    Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof.
    Type: Application
    Filed: January 3, 2020
    Publication date: March 10, 2022
    Inventors: Robert G. Lowery, Meera Kumar, Matthew Boxer, David Maloney, Susan Boyd